SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14 at 8:00 a.m. PT in San Francisco, California.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-stage clinical biotechnology company dedicated to transforming cutting-edge science into next-generation RNA medicines across a wide range of therapeutic areas. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. We are focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, initially developing our product candidates for the treatment of complement-mediated, genetic, cardiovascular, central nervous system and metabolic (obesity) diseases. Follow ADARx on LinkedIn.
CONTACT: Media Contact: Teri Dahlman Red House Communications teri@redhousecomms.com
Now Accepting Nomination Submissions for the Prestigious Annual AwardToronto, Ontario--(Newsfile Corp. - February 4, 2026)…
DRAPER, UTAH / ACCESS Newswire / February 4, 2026 / CenExel, a leading, wholly owned…
BOCA RATON, FL / ACCESS Newswire / February 4, 2026 / GridAI Technologies Corp. (Nasdaq:GRDX),…
Targeting Q1 2026 Launch, Subject to FDA ClearanceKey Highlights:Cartridge & Infusion Set Lots in Production:…
New Market Briefing From Black Book Research Highlights 80% of Surveyed Hospitals Active in EHR…
BOULDER, CO / ACCESS Newswire / February 4, 2026 / Encision Inc. (OTC PINK:ECIA), a…